Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). Co. is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer's pathology). The ABOS stock yearly return is shown above.
The yearly return on the ABOS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2024 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ABOS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|